Acrivon Therapeutics (ACRV) Stock Forecast & Price Target

$7.19

-0.04 (-0.55%)

(As of 09/24/2024 ET)

Acrivon Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 7 Analyst Ratings

Sell
0

Hold
0

Buy
7

Based on 7 Wall Street analysts who have issued ratings for Acrivon Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 7 have given a buy rating for ACRV.

Consensus Price Target

$23.86
231.81% Upside

According to the 7 analysts' twelve-month price targets for Acrivon Therapeutics, the average price target is $23.86. The highest price target for ACRV is $30.00, while the lowest price target for ACRV is $16.00. The average price target represents a forecasted upside of 231.81% from the current price of $7.19.

Get the Latest News and Ratings for ACRV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Acrivon Therapeutics and its competitors.

ACRV Analyst Ratings Over Time

Type	Current Forecast 9/26/23 to 9/25/24	1 Month Ago 8/27/23 to 8/26/24	3 Months Ago 6/28/23 to 6/27/24	1 Year Ago 9/26/22 to 9/26/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)	9 Buy rating(s)
Hold	0 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$23.86	$22.00	$22.57	$22.86
Forecasted Upside	231.81% Upside	132.56% Upside	291.87% Upside	155.39% Upside
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Buy

Urgent 2024 Election Summit [link enclosed] (Ad)

With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election.

Click here now to grab your seat now.

ACRV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ACRV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Acrivon Therapeutics Stock vs. The Competition

Type	Acrivon Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	231.81% Upside	915.62% Upside	6.80% Upside
News Sentiment Rating	Positive News See Recent ACRV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/16/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Outperform	$17.00 ➝ $17.00	+77.45%
9/16/2024	BMO Capital Markets 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$25.00 ➝ $28.00	+194.74%
9/16/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00	+146.91%
9/16/2024	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Huseynov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$16.00	+79.57%
9/6/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$30.00	+266.75%
10/5/2023	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$24.00	+213.32%
Get the Latest News and Ratings for ACRV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
8/18/2023	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$26.00	+135.51%
6/1/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$25.00	+101.29%
12/12/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$17.00	+36.00%
12/12/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:25 AM ET.

ACRV Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Acrivon Therapeutics is $23.86, with a high forecast of $30.00 and a low forecast of $16.00.
: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACRV shares.
: According to analysts, Acrivon Therapeutics's stock has a predicted upside of 231.81% based on their 12-month stock forecasts.
: Over the previous 90 days, Acrivon Therapeutics's stock had 1 upgrade by analysts.
: Acrivon Therapeutics has been rated by research analysts at BMO Capital Markets, HC Wainwright, JMP Securities, LADENBURG THALM/SH SH, and Piper Sandler Companies in the past 90 days.
: Analysts like Acrivon Therapeutics more than other "medical" companies. The consensus rating for Acrivon Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ACRV compares to other companies.